Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less / ESMO

esmo - Findings from the POSEIDON meta-analysis of the MARCAP consortium

#healthcare #pharmaceuticals #publichealth #oncology


Thursday, March 5, 2026, 3:23 am / permalink 20175 / 3 stories in 6 days



Related Stories




Related Tags



StackHealth Time Machine





NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.